Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine.

<h4>Background</h4>A therapeutic vaccine for chronic hepatitis B virus (HBV) infection that enhances virus-specific cellular immune responses is urgently needed. The "prime-boost" regimen is a widely used vaccine strategy against many persistence infections. However, few report...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hong Chen, Xia Chuai, Yao Deng, Bo Wen, Wen Wang, Shaoqing Xiong, Li Ruan, Wenjie Tan
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7df43b65b6dd4569ab70422fdcfff997
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7df43b65b6dd4569ab70422fdcfff997
record_format	dspace
spelling	oai:doaj.org-article:7df43b65b6dd4569ab70422fdcfff9972021-11-18T07:06:28ZOptimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine.1932-620310.1371/journal.pone.0043730https://doaj.org/article/7df43b65b6dd4569ab70422fdcfff9972012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22970140/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>A therapeutic vaccine for chronic hepatitis B virus (HBV) infection that enhances virus-specific cellular immune responses is urgently needed. The "prime-boost" regimen is a widely used vaccine strategy against many persistence infections. However, few reports have addressed this strategy applying for HBV therapeutic vaccine development.<h4>Methodology/principal findings</h4>To develop an effective HBV therapeutic vaccine, we constructed a recombinant vaccinia virus (Tiantan) containing the S+PreS1 fusion antigen (RVJSS1) combined with the HBV particle-like subunit vaccine HBVSS1 to explore the most effective prime-boost regimen against HBV. The immune responses to different prime-boost regimens were assessed in C57BL/C mice by ELISA, ELISpot assay and Intracellular cytokine staining analysis. Among the combinations tested, an HBV protein particle vaccine priming and recombinant vaccinia virus boosting strategy accelerated specific seroconversion and produced high antibody (anti-PreS1, anti-S antibody) titres as well as the strongest multi-antigen (PreS1, and S)-specific cellular immune response. HBSS1 protein prime/RVJSS1 boost immunization was also generated more significant level of both CD4+ and CD8+ T cell responses for Th1 cytokines (TNF-α and IFN-γ).<h4>Conclusions</h4>The HBSS1 protein-vaccine prime plus RVJSS1 vector boost elicits specific antibody as well as CD4 and CD8 cells secreting Th1-like cytokines, and these immune responses may be important parameters for the future HBV therapeutic vaccines.Hong ChenXia ChuaiYao DengBo WenWen WangShaoqing XiongLi RuanWenjie TanPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 9, p e43730 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hong Chen Xia Chuai Yao Deng Bo Wen Wen Wang Shaoqing Xiong Li Ruan Wenjie Tan Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine.
description	<h4>Background</h4>A therapeutic vaccine for chronic hepatitis B virus (HBV) infection that enhances virus-specific cellular immune responses is urgently needed. The "prime-boost" regimen is a widely used vaccine strategy against many persistence infections. However, few reports have addressed this strategy applying for HBV therapeutic vaccine development.<h4>Methodology/principal findings</h4>To develop an effective HBV therapeutic vaccine, we constructed a recombinant vaccinia virus (Tiantan) containing the S+PreS1 fusion antigen (RVJSS1) combined with the HBV particle-like subunit vaccine HBVSS1 to explore the most effective prime-boost regimen against HBV. The immune responses to different prime-boost regimens were assessed in C57BL/C mice by ELISA, ELISpot assay and Intracellular cytokine staining analysis. Among the combinations tested, an HBV protein particle vaccine priming and recombinant vaccinia virus boosting strategy accelerated specific seroconversion and produced high antibody (anti-PreS1, anti-S antibody) titres as well as the strongest multi-antigen (PreS1, and S)-specific cellular immune response. HBSS1 protein prime/RVJSS1 boost immunization was also generated more significant level of both CD4+ and CD8+ T cell responses for Th1 cytokines (TNF-α and IFN-γ).<h4>Conclusions</h4>The HBSS1 protein-vaccine prime plus RVJSS1 vector boost elicits specific antibody as well as CD4 and CD8 cells secreting Th1-like cytokines, and these immune responses may be important parameters for the future HBV therapeutic vaccines.
format	article
author	Hong Chen Xia Chuai Yao Deng Bo Wen Wen Wang Shaoqing Xiong Li Ruan Wenjie Tan
author_facet	Hong Chen Xia Chuai Yao Deng Bo Wen Wen Wang Shaoqing Xiong Li Ruan Wenjie Tan
author_sort	Hong Chen
title	Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine.
title_short	Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine.
title_full	Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine.
title_fullStr	Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine.
title_full_unstemmed	Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine.
title_sort	optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (tiantan)-based hbv vaccine.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/7df43b65b6dd4569ab70422fdcfff997
work_keys_str_mv	AT hongchen optimisationofprimeboostimmunizationinmiceusingnovelproteinbasedandrecombinantvacciniatiantanbasedhbvvaccine AT xiachuai optimisationofprimeboostimmunizationinmiceusingnovelproteinbasedandrecombinantvacciniatiantanbasedhbvvaccine AT yaodeng optimisationofprimeboostimmunizationinmiceusingnovelproteinbasedandrecombinantvacciniatiantanbasedhbvvaccine AT bowen optimisationofprimeboostimmunizationinmiceusingnovelproteinbasedandrecombinantvacciniatiantanbasedhbvvaccine AT wenwang optimisationofprimeboostimmunizationinmiceusingnovelproteinbasedandrecombinantvacciniatiantanbasedhbvvaccine AT shaoqingxiong optimisationofprimeboostimmunizationinmiceusingnovelproteinbasedandrecombinantvacciniatiantanbasedhbvvaccine AT liruan optimisationofprimeboostimmunizationinmiceusingnovelproteinbasedandrecombinantvacciniatiantanbasedhbvvaccine AT wenjietan optimisationofprimeboostimmunizationinmiceusingnovelproteinbasedandrecombinantvacciniatiantanbasedhbvvaccine
_version_	1718423923597508608

Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine.

Ejemplares similares